ASX:ZLD

Zelira Therapeutics (ZLD) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
311,821 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
8.62%
Price Target
N/A

About Zelira Therapeutics

Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.

ZLD Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive ZLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zelira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2019
Today
4/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-36,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.54 million
Book Value
A($0.21) per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.52
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Osagie O. Imasogie Esq. (Age 62)
    Founder & Chairman
    Comp: $144k
  • Dr. Oludare Odumosu
    MD, Global CEO & Director
  • Mr. Greg Blake
    Executive Director
  • Mr. Timothy Ryan Slate
    Company Secretary & Non-Executive Director
  • Mr. Rahul Ganesan
    Vice President of Finance & Accounting
  • Dr. Patty Washer
    Clinical Trial Consultant

ZLD Stock Analysis - Frequently Asked Questions

How were Zelira Therapeutics' earnings last quarter?

Zelira Therapeutics Limited (ASX:ZLD) issued its quarterly earnings results on Friday, February, 22nd. The company reported $0.00 EPS for the quarter.

What other stocks do shareholders of Zelira Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zelira Therapeutics investors own include Saputo (SAP), Western Union (WU), Intuitive Surgical (ISRG) and Heat Biologics (HTBX).

This page (ASX:ZLD) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners